An interventional study of Standard Clinical Ear Exam and AI app ear exam and diagnosis in Acute Otitis Media (AOM) and Upper Respiratory Infection, sponsored by Timothy Shope. Recruiting at 2 sites in United States. Open to participants aged 6 Months to 24 Months. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Timothy Shope · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies in Otitis Media with a site in United States — 12 open to participants now, 23 under way, none of them phase 3. Otitis Media · United States.
Among the 110 studies in Otitis Media with a site in United States, this one is the 24th largest by planned enrollment of the 85 interventional ones that give a count, is one of 7 that started in 2025, is one of 40 with no phase, reaches primary completion later than 7 of the 22 other live ones, and was the 100th registered.
244 studies on the registry are indexed under Otitis Media; 34 are open to participants now.
Browse Otitis Media studies →12 of the 110 studies in Otitis Media with a site in United States are open now. Recruiting first, the newest first:
Nader Shaikh · Sites in United States
Ages 6 mo–36 mo
ClinQure, Inc. · Sites in United States
Ages 6 mo+
Stanford University · Sites in United States
Ages 1–17
Medentum Innovations · Sites in United States
Ages 3–17 · Healthy volunteers
Serum Life Science Europe GmbH · Sites in United States
Ages 5 mo–7 mo · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 20 Otitis Media studies recruiting now, 5 (25%) set no upper age limit and 15 (75%) stop at 75 or younger; 19 take children under 18; 4 take healthy volunteers.
This study: 6 Months to 24 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 15 · Phase 3 21 · Phase 4 9
First in 1997; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 168 across 177 interventional studies indexed under Otitis Media.
Median enrollment 119 across the 85 interventional studies, 200 across the 23 observational. Of the 84 that completed or were terminated, 42 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 110 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Timothy Shope as lead sponsor.
Timothy Shope has 1 study filed under Otitis Media — fewer than ten, so there is no comparison to draw.
8 of the studies in Otitis Media with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06876259Timothy ShopeArtificial Intelligence Diagnostic Decision Support to Reduce Antimicrobial Prescriptions in Young Children With Colds | 2027-03-30 |
| NCT07328555Boston Children's HospitalDigital Otoscopy Versus Standard Otoscopy on the Diagnosis and Treatment of Otitis Media in Young Children | 2027-03-31 |
| NCT05608993Intermountain Health Care, Inc.RELAX: Reducing Length of Antibiotics for Children With Ear Infections | 2027-04 |
| NCT05353569Medical College of WisconsinCoherent Optical Detection of Middle Ear Disease | 2027-04 |
| NCT06944795Stanford UniversitySWIR Otoscopy Study | 2027-04-30 |
Add all 8 to your calendar (.ics) → With an account.
Among the 110 studies in Otitis Media with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Ear infections are common in young children with cold symptoms, but they can be difficult to diagnose due to small ear canals, child movement, and limited viewing time. In this study, investigators will take photos of the eardrums of children 6-24 months of age with upper respiratory symptoms. The photos will be reviewed by imaging software enhanced with artificial intelligence (AI app) to determine whether the AI app changes how ear infections are diagnosed and treated. The AI app has undergone rigorous study and was found to be highly accurate; but how using this technology affects the diagnosis and treatment by clinicians has not been studied. This research may help improve diagnostic accuracy for ear infections and ensure antibiotics are prescribed only for those children who have definite ear infections.
Participants and Setting This will be a 12-month, within-subject design, single center study of 300 children 6 to 24 months of age presenting to their primary care providers at Children's Community Pediatrics offices with upper respiratory symptoms. Exclusion criteria are children with tympanostomy tubes or purulent otorrhea, absence of upper respiratory symptoms, or who are currently taking antimicrobials.
Design and Outcomes
Using a double blind, within-subject design, each child's ear will be assessed by the AI app and a standard clinical exam. The primary outcome measure will be antimicrobial prescription rates derived from 150 paired images that each have an AI app and clinician diagnosis. We will secondarily assess acute otitis media (AOM) diagnosis rates. If the AI app diagnoses AOM it will always prescribe an antimicrobial. Secondary outcomes are described below:
Sample Size Calculation Using paired observations (AI app vs clinician antimicrobial prescription recommendations), an estimated 300 children 6 to 24 months of age presenting to primary care practices with upper respiratory symptoms will need to be enrolled to derive 150 paired interpretable images to detect a 10% difference in AOM diagnosis and subsequent antimicrobial prescription rates between the AI app and clinicians, assuming a power of 80% and two-sided p-value \<0.05. This assumes 15% of children in the target population will truly have AOM, and clinicians will diagnose and treat AOM at a 10% higher rate (25%) compared to the AI app. If clinicians reconcile and follow the app diagnosis and treatment recommendations, this will equate to a 40% reduced/avoidable antimicrobial prescription rate. This estimate accounts for two ears per child and estimates 50% of images will be uninterpretable by the app, and 50% of clinician exams will not result in a diagnosis.
Statistical analysis All analyses will be conducted by a statistician in the General Academic Pediatrics Division, Department of Pediatrics.
The primary outcome of antimicrobial prescription rates will be assessed by the McNemar's Test. Differences in secondary outcomes will be assessed by generalized estimating equation (symptom score) and chi square test (antimicrobial side effects and recurrent AOM).
Descriptive outcomes (uninterpretable images, clinician ability to make a diagnosis, AOM diagnosis, antimicrobial prescriptions) will be reported as rates (%).
Study Procedures:
Screening: Office schedules will be screened to identify children in the eligible age group who are presenting with upper respiratory symptoms.
Consent: Once age-eligible children have checked in to the office their parents will be approached by research personnel to assess their interest in the study and eligibility. Informed consent will be obtained after rooming.
Study Procedures:
The duration of the study procedures, not including standard clinical care, will be about 10 minutes. After consent, each participating child will have two ear exams.
Clinicians will complete a "final outcome" indicating whether antimicrobials were prescribed and the reason for prescription.
Data will be recorded in an electronic database.
Demographic Information:
Research staff will obtain demographic information after the study procedures (duration: 60 seconds).
Follow-up:
All participants will be followed for 10 days to assess symptom resolution and side effects of antimicrobial use. AOM symptoms will be monitored daily for 10 days using a validated symptom scale entered once every evening (duration: 60 seconds), whether on antimicrobial therapy or not, by parents in electronic diaries which have used by our team in many other studies. If any participant increases their symptoms score by >20% at any time, they will be contacted and offered a visit. Rates of protocol-defined diarrhea and diaper rash which are the most common side effects of antimicrobial use in this age group will also be assessed. Finally, AOM recurrences will be monitored by reviewing the electronic medical record for 3 months following enrollment.
Duration:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Using a within subject design, each child's ear will be in the experimental and standard care group. Each ear will be examined by the AI app and a clinician (blinded to the AI app diagnosis) to provide a diagnosis and treatment recommendation.
Diagnostic Test: Standard Clinical Ear Exam · Diagnostic Test: AI app ear exam and diagnosis
The clinician will examine the child's ear with a standard otoscope and give a clinical diagnosis and decision to treat with antibiotics.
Using a standard otoscope with a cell phone mounted to it, research personnel will record a video image of the tympanic membrane and send it to the cloud for analysis using AI enhanced classification software to render a diagnosis and treatment recommendation
Antimicrobial prescription rate
The rate of antimicrobial prescriptions will be compared between standard care and AI app groups.
Time frame: Day 1
Acute otitis media diagnosis rate
The rate of diagnosis of acute otitis media will be compared between standard clinical examination and the AI app
Time frame: Day 1
Uninterpretable image rate
The rate of AI app and clinician interpretable images among enrolled participants
Time frame: Day 1
Acute Otitis Media Severity of Symptoms (AOM-SOS) Scale version 6
A validated and reliable 10-item scale for measuring AOM symptom burden. Responses for each item are scored 0-5 and the total score minimum is 0 and maximum is 50. Higher values represent more severe symptoms.
Time frame: From enrollment to 11 days after enrollment
Acute otitis media recurrences
All participants with paired clinician and AI app images in the same ear will be followed for 3 months to assess recurrences of AOM. This will be determined from diagnostic codes entered into the electronic medical record. A new AOM diagnosis must be at least 14 days after the previous diagnosis. AOM recurrences will be expressed as total counts among participants and total counts among ears.
Time frame: From enrollment to 3 months from enrollment
Plan to share: No
Started Dec 2025 (actual). Primary completion is estimated for Mar 2027, 15 months after the start.
Of 37 non-industry interventional studies with no phase under Otitis Media, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 64. This study's planned 15 months is below that.
Counting every sponsor, half of 46 studies reached it within 38 months; a quarter within 13 and three quarters within 51.
Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Mar 2027, on Oct 8, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.